Revelation Biosciences Inc (REVB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.43M
Last updated: Nov 17, 2026 at 11:00 AM ET
Revelation Biosciences Inc (REVB) Earnings: Report Dates and Results
Revelation Biosciences (REVB) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Revelation Biosciences reported EPS of -$5.92, above the -$6.16 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
REVB has an expected report date of Feb 24, 2027.
Earnings History
Of the 24 quarters below that had an estimate, REVB beat 13, missed 10 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2023, when EPS landed 529.23% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$5.92 | -$6.16 | -$6.58 - -$5.74 | +3.90% | Beat | N/A | 2 | 0 up, 0 down | Nov 5, 2026 | N/A |
| Jun 30, 2026 | -$0.87 | -$0.83 | -$0.88 - -$0.78 | -4.82% | Miss | N/A | 2 | 0 up, 0 down | Aug 7, 2026 | N/A |
| Mar 31, 2026 | -$2.71 | -$1.15 | -$1.55 - -$0.75 | -135.65% | Miss | N/A | 2 | 0 up, 0 down | May 7, 2026 | N/A |
| Dec 31, 2025 | -$1.65 | -$1.41 | -$6.00 - -$1.32 | -17.02% | Miss | N/A | 2 | 0 up, 0 down | Feb 26, 2026 | N/A |
| Sep 30, 2025 | -$7.08 | -$5.34 | -$6.48 - -$4.20 | -32.58% | Miss | N/A | 2 | 0 up, 0 down | Nov 6, 2025 | N/A |
| Jun 30, 2025 | -$7.01 | -$4.46 | -$6.15 - -$2.76 | -57.17% | Miss | N/A | 2 | 2 up, 0 down | Aug 7, 2025 | N/A |
| Mar 31, 2025 | -$25.32 | -$27.52 | -$30.00 - -$11.28 | +7.98% | Beat | N/A | 2 | 1 up, 0 down | May 8, 2025 | N/A |
| Dec 31, 2024 | -$4.98 | -$10.32 | -$15.20 - -$5.44 | +51.74% | Beat | N/A | 2 | 1 up, 0 down | Mar 6, 2025 | $26964 |
| Sep 30, 2024 | -$161.28 | -$545.28 | -$908.25 - -$182.42 | +70.42% | Beat | N/A | 2 | 0 up, 0 down | Nov 8, 2024 | N/A |
| Jun 30, 2024 | -$984.96 | -$346.56 | -$435.88 - -$257.31 | -184.21% | Miss | N/A | 2 | 0 up, 0 down | Aug 9, 2024 | N/A |
| Mar 31, 2024 | -$472.32 | -$1,033.92 | -$1,728.17 - -$339.87 | +54.32% | Beat | -17029.0% | 2 | 0 up, 0 down | May 10, 2024 | N/A |
| Dec 31, 2023 | -$8.33 | -$13.77 | -$13.77 - -$13.77 | +39.51% | Beat | N/A | 1 | 1 up, 0 down | Mar 22, 2024 | $37574 |
| Sep 30, 2023 | -$2,488.78 | -$1,929.60 | -$1,960.56 - -$1,499.25 | -28.98% | Miss | N/A | 2 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$1,854.72 | -$1,872.00 | N/A | +0.92% | Beat | N/A | 1 | 0 up, 0 down | Aug 11, 2023 | N/A |
| Mar 31, 2023 | $2.79 | -$0.65 | -$0.65 - -$0.65 | +529.23% | Beat | N/A | 1 | 0 up, 0 down | May 22, 2023 | N/A |
| Dec 31, 2022 | -$12,904.14 | -$10,080.01 | N/A | -28.02% | Miss | N/A | 1 | 0 up, 0 down | Mar 30, 2023 | N/A |
| Sep 30, 2022 | -$12,096.03 | -$18,144.04 | N/A | +33.33% | Beat | N/A | 1 | 0 up, 0 down | Nov 10, 2022 | N/A |
| Jun 30, 2022 | -$24,192.05 | -$28,224.06 | N/A | +14.29% | Beat | N/A | 1 | 0 up, 0 down | Aug 15, 2022 | N/A |
| Mar 31, 2022 | -$94,752.20 | -$28,224.06 | N/A | -235.71% | Miss | N/A | 1 | 0 up, 0 down | Apr 15, 2022 | N/A |
| Dec 31, 2021 | -$206,568.84 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2021 | N/A |
| Sep 30, 2021 | -$0.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Oct 29, 2021 | N/A |
| Jun 30, 2021 | -$0.73 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 23, 2021 | N/A |
| Mar 31, 2021 | -$0.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 22, 2021 | N/A |
| Dec 31, 2020 | -$251,590.87 | N/A | N/A | N/A | N/A | -38706388.0% | N/A | N/A | Mar 31, 2021 | N/A |
| Sep 30, 2020 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Nov 16, 2020 | N/A |
| Dec 31, 2019 | $0.65 | N/A | N/A | N/A | N/A | +10.2% | N/A | N/A | Jan 28, 2020 | $25.07M |
| Sep 30, 2019 | $0.69 | $0.68 | $0.66 - $0.69 | +1.47% | Beat | +6.2% | 2 | N/A | Oct 24, 2019 | $24.84M |
| Jun 30, 2019 | $0.65 | $0.64 | N/A | +1.56% | Beat | N/A | 1 | N/A | Jul 24, 2019 | $23.74M |
| Mar 31, 2019 | $0.62 | $0.61 | $0.60 - $0.61 | +1.64% | Beat | N/A | 2 | N/A | Apr 29, 2019 | $22.16M |
| Dec 31, 2018 | $0.59 | $0.61 | $0.60 - $0.61 | -3.28% | Miss | N/A | 2 | N/A | Jan 29, 2019 | $21.45M |
| Sep 30, 2018 | $0.65 | $0.65 | $0.65 - $0.65 | 0.00% | In line | N/A | 1 | N/A | Nov 9, 2018 | $20.63M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$41.06, after -$1,623.54 the year before. It was $1.24 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$41.06 | N/A |
| Dec 31, 2024 | -$1,623.54 | N/A |
| Dec 31, 2023 | -$4,349.04 | N/A |
| Dec 31, 2022 | -$143,944.42 | N/A |
| Dec 31, 2021 | -$206,570.15 | N/A |
| Dec 31, 2020 | -$251,590.87 | -9639597.0% |
| Dec 31, 2019 | $2.61 | +110.5% |
| Dec 31, 2018 | $1.24 | N/A |
Frequently Asked Questions About REVB
When is Revelation Biosciences's next earnings date?
Revelation Biosciences's next earnings report is expected for Feb 24, 2027.
Did REVB beat earnings estimates last quarter?
Yes. Revelation Biosciences reported EPS of -$5.92 for the quarter ended Sep 30, 2026, above the -$6.16 estimate, a 3.90% surprise.
What EPS do analysts expect from REVB next quarter?
The consensus EPS estimate for Revelation Biosciences for the quarter ending Dec 31, 2026 is -$6.20 from 4 analysts, with estimates from -$6.45 to -$5.86.
How often does REVB beat earnings estimates?
Revelation Biosciences beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -22.95%.
REVB pages: Overview, Earnings, Forecast, Financials, Competitors